Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Follow-Up Questions
Incyte Corp (INCY)의 PER은 얼마입니까?
Incyte Corp의 PER은 508.682입니다
Incyte Corp의 CEO는 누구입니까?
Mr. Bill Meury은 2025부터 회사에 합류한 Incyte Corp의 President입니다.
INCY 주식의 가격 성능은 어떻습니까?
INCY의 현재 가격은 $104.01이며, 전 거래일에 increased 2.4% 하였습니다.
Incyte Corp의 주요 사업 주제나 업종은 무엇입니까?
Incyte Corp은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Incyte Corp의 시가총액은 얼마입니까?
Incyte Corp의 현재 시가총액은 $20.3B입니다
Incyte Corp는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 24명의 분석가가 Incyte Corp에 대한 분석 평가를 실시했으며, 이는 10명의 강력한 매수, 8명의 매수, 15명의 보유, 1명의 매도, 그리고 10명의 강력한 매도를 포함합니다
